欧洲额颞叶变性相关综合征患者入住养老院与生存率的预测因素
基于欧洲FRONTIERS登记的前瞻性纵向多国观察性研究,纳入2018年6月1日至2019年5月31日诊断的266例额颞叶变性相关综合征患者,随访至2023年5月31日。从诊断起算中位生存49个月,从起病起算中位生存90个月;从诊断起算中位入住养老院时间57个月。FTD-MND和PSP/CBS的生存率较bvFTD更差。生存概率评分(SPS)预测1年生存的AUC为0.789。
要点
- 从诊断起算中位生存49个月(95%CI 44-58),从起病起算90个月(95%CI 77-97)。
- FTD-MND较bvFTD生存更短(HR 4.59,95%CI 2.49-8.76,p<0.001)。
- SPS预测1年生存的AUC为0.789(95%CI 0.69-0.87)。
核心结论
- 在额颞叶变性相关综合征中,生存率因临床特征和地理区域而异。
- SPS能以约80%的准确度预测个体患者预后,可能有助于改善临床试验中的患者分层。
- 需要未来在不同人群中开展验证性研究。
研究设计与样本
- 前瞻性纵向多国观察性登记研究,纳入2018年6月1日至2019年5月31日诊断的266例额颞叶变性相关综合征患者,随访至2023年5月31日(最长5年)。
- 纳入诊断包括行为变异型额颞叶痴呆(bvFTD)、原发性进行性失语(PPA)、进行性核上性麻痹(PSP)、皮质基底节综合征(CBS)及额颞叶痴呆伴运动神经元病(FTD-MND)。
- 采用Kaplan-Meier分析和Cox多变量回归模型评估入住养老院率和生存率,并基于独立生存预测因素计算生存概率评分(SPS)。
主要发现
- 中位入住养老院时间:从起病起算97个月(95%CI 86-98),从诊断起算57个月(95%CI 56-58)。
- 中位生存时间:从起病起算90个月(95%CI 77-97),从诊断起算49个月(95%CI 44-58)。
- 从诊断起算,FTD-MND生存较bvFTD更短(HR 4.59,95%CI 2.49-8.76,p<0.001),PSP/CBS生存较bvFTD更短(HR 1.56,95%CI 1.01-2.42,p=0.044)。
- PPA与bvFTD之间生存无显著差异。
- SPS由诊断时年龄、欧洲居住区域、锥体外系症状和运动神经元病定义,预测1年生存概率的AUC为0.789(95%CI 0.69-0.87)。
临床怎么用
- 作者认为SPS能以约80%的准确度预测个体患者预后,可能有助于改善临床试验中的患者分层。
局限性
- 原文指出需要未来在不同人群中开展验证性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Data on care home admission and survival rates of patients with syndromes associated with frontotemporal lobar degeneration (FTLD) are limited. However, their estimation is essential to plan trials and assess the efficacy of intervention. Population-based registers provide unique samples for this estimate. The aim of this study was to assess care home admission rate, survival rate, and their predictors in incident patients with FTLD-associated syndromes from the European FRONTIERS register-based study. METHODS: We conducted a prospective longitudinal multinational observational registry study, considering incident patients with FTLD-associated syndromes diagnosed between June 1, 2018, and May 31, 2019, and followed for up to 5 years till May 31, 2023. We enrolled patients fulfilling diagnosis of the behavioral variant frontotemporal dementia (bvFTD), primary progressive aphasia (PPA), progressive supranuclear palsy (PSP) or corticobasal syndrome (CBS), and FTD with motor neuron disease (FTD-MND). Kaplan-Meier analysis and Cox multivariable regression models were used to assess care home admission and survival rates. The survival probability score (SPS) was computed based on independent predictors of survivorship. RESULTS: A total of 266 incident patients with FTLD were included (mean age ± SD = 66.7 ± 9.0; female = 41.4%). The median care home admission rate was 97 months (95% CIs 86-98) from disease onset and 57 months (95% CIs 56-58) from diagnosis. The median survival was 90 months (95% CIs 77-97) from disease onset and 49 months (95% CIs 44-58) from diagnosis. Survival from diagnosis was shorter in FTD-MND (hazard ratio [HR] 4.59, 95% CIs 2.49-8.76, p < 0.001) and PSP/CBS (HR 1.56, 95% CIs 1.01-2.42, p = 0.044) compared with bvFTD; no differences between PPA and bvFTD were found. The SPS proved high accuracy in predicting 1-year survival probability (area under the receiver operating characteristic curve = 0.789, 95% CIs 0.69-0.87), when defined by age, European area of residency, extrapyramidal symptoms, and MND at diagnosis. DISCUSSION: In FTLD-associated syndromes, survival rates differ according to clinical features and geography. The SPS was able to predict prognosis at individual patient level with an accuracy of ∼80% and may help to improve patient stratification in clinical trials. Future confirmatory studies considering different populations are needed.
引用
- Borroni B, Tarantino B, Graff C, et al. Predictors of Care Home Admission and Survival Rate in Patients With Syndromes Associated With Frontotemporal Lobar Degeneration in Europe. Neurology. 2024. PMID: 39226519. doi:10.1212/WNL.0000000000209793
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。